Mammary-analog secretory carcinoma in children: Surgery or TRK inhibitors first?
NTRK fusion
TRK inhibitor
entrectinib
larotrectinib
mammary analog secretory carcinoma
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
20 Jun 2023
20 Jun 2023
Historique:
revised:
15
05
2023
received:
28
04
2023
accepted:
05
06
2023
medline:
20
6
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
aheadofprint
Résumé
We report two cases of pediatric mammary-analog secretory carcinoma (MASC), a male operated on at age 8 and a female operated on at 12, who are in remission 2 years after surgery. The diagnosis of MASC was challenging and established by identifying the ETV6::NTRK3 fusion transcript in both cases. Given the excellent results of TRK inhibitor treatments in adult MASC and pediatric tumors expressing an ETV6::NTRK3 fusion, they should probably be prescribed as first-line treatment in cases requiring surgery with foreseeable serious sequelae or metastatic disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30504Informations de copyright
© 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Kelly GA, Venkatramani R, Quintanilla NM, Chelius DC, Roy A, Mahajan P. Secretory carcinoma of the salivary gland: a rarity in children. J Pediatr Hematol Oncol. 2022;44:167-172.
Ding A, Zuo J, Lv H, et al. Imaging identification of primary mammary analogue secretory carcinoma and acinic cell carcinoma in major salivary glands. Oral Dis. 2022;28:1861-1870.
Parekh V, Stevens TM. Mammary analogue secretory carcinoma. Arch Pathol Lab Med. 2016;140:997-1001.
Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013;7(1):S30-S36.
Blauel ER, Laetsch TW. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Cancer Genet. 2022;262-263:71-79.
Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW. TRK fusion cancers in children: a clinical review and recommendations for screening. J Clin Oncol. 2019;37:513-524.
Le X, Baik C, Bauman J, et al. Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist. 2022:oyac080. doi:10.1093/oncolo/oyac080
Bill R, Deschler DG, Pittet MJ, Pai SI, Sadow PM, Park JC. Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands. Cancer Rep (Hoboken). 2022;5:e1491.
Ernst MS, Lysack JT, Hyrcza MD, Chandarana SP, Hao D. TRK inhibition with entrectinib in metastatic salivary secretory carcinoma (SC): a case report. Curr Oncol. 2022;29:3933-3939.
Yokota T, Yukino H, Doi M, Ohori H. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: a case series. Head Neck. 2023;45:E10-E15.
Meneses-Lorente G, Guerini E, Mercier F, et al. Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations. Cancer Chemother Pharmacol. 2023;91:239-246.